Latest Conference Articles

January 18th 2019, 2:33am

SGO Winter Meeting

Several ongoing trials are examining combinations of PARP inhibitors and immunotherapy agents as frontline maintenance for patients with ovarian cancer.

December 11th 2018, 8:31pm

ASH Annual Meeting and Exposition

Krish Patel, MD, oncologist, Swedish Cancer Institute, discusses induction therapy with bendamustine and rituximab (Rituxan; BR) in the treatment of patients with mantle cell lymphoma (MCL).

December 11th 2018, 8:29pm

ASH Annual Meeting and Exposition

Jordan Gauthier, MD, MSc, senior clinical research fellow, Fred Hutchinson Cancer Research Center, discusses the potential for chimeric antigen receptor T-cell therapy in the treatment of chronic lymphocytic leukemia.

December 10th 2018, 9:39pm

San Antonio Breast Cancer Symposium

Chemotherapy for breast cancer caused significantly more acute symptoms as compared with endocrine therapy, although the adverse effects of endocrine therapy increased over time.

December 8th 2018, 4:01am

San Antonio Breast Cancer Symposium

Chimeric antigen receptor T cells targeting the tyrosine kinase receptor ROR1 can be transferred into patients safely and the cells expand in vivo.

December 8th 2018, 1:07am

San Antonio Breast Cancer Symposium

Early-stage breast cancer survivors who completed a telephone-based lifestyle intervention program lost weight and tended to have higher rates of disease-free survival.

December 8th 2018, 12:10am

San Antonio Breast Cancer Symposium

The combination of olaparib and durvalumab in patients with HER2-negative metastatic breast cancer with germline BRCA mutations is well tolerated and has promising activity, especially in earlier settings.

December 8th 2018, 12:03am

San Antonio Breast Cancer Symposium

Younger patients with breast cancer who underwent lumpectomy had better quality of life than women who had a mastectomy.

December 7th 2018, 10:39pm

San Antonio Breast Cancer Symposium

Women who took part in a supervised exercise program during adjuvant treatment for breast cancer had better cardiovascular function than women who did not participate in the program.

December 7th 2018, 10:26pm

San Antonio Breast Cancer Symposium

The combination of palbociclib and trastuzumab demonstrated safety and efficacy in patients with advanced estrogen receptor–positive/HER2-positive breast cancer.

December 7th 2018, 10:13pm

San Antonio Breast Cancer Symposium

Oxybutynin helped to reduce the frequency and intensity of hot flashes among women who could not take hormone replacement therapy in survivorship.

December 7th 2018, 9:25pm

San Antonio Breast Cancer Symposium

Combining the BCL-2 inhibitor venetoclax with endocrine therapy elicited notable activity with a tolerable safety profile in patients with estrogen receptor–positive and BCL-2–positive metastatic breast cancer.

December 7th 2018, 7:49pm

San Antonio Breast Cancer Symposium

Laura Spring, MD, medical oncologist at Massachusetts General Hospital Cancer Center and instructor in medicine at Harvard Medical School, discusses the association between pathologic complete response (pCR) and neoadjuvant chemotherapy in patients with breast cancer at the 2018 San Antonio Breast Cancer Symposium.

December 7th 2018, 7:47pm

San Antonio Breast Cancer Symposium

Roberto A. Leon Ferre, MD, oncologist, Mayo Clinic, discusses the randomized trial evaluating the effectiveness of oxybutynin chloride in the management of hot flashes in patients with breast cancer at the 2018 San Antonio Breast Cancer Symposium.

December 7th 2018, 3:06am

San Antonio Breast Cancer Symposium

Additional analyses from the SOLAR-1 study show that alpelisib, an investigational alpha-specific PI3K inhibitor, combined with fulvestrant extended progression-free survival compared with fulvestrant alone in patients with PIK3CA-mutant advanced breast cancer regardless of line of therapy or prior CDK4/6 inhibitor treatment.

December 7th 2018, 2:21am

San Antonio Breast Cancer Symposium

U3-1402, an investigational antibody-drug conjugate targeting HER3, induced objective response in more than 40% of heavily pretreated patients with HER3-expressing breast cancer.

December 7th 2018, 1:40am

San Antonio Breast Cancer Symposium

Axillary radiotherapy was associated with locoregional control comparable to that with axillary lymph node dissection in patients with early-stage breast cancer who had a positive sentinel lymph node biopsy.

December 7th 2018, 12:44am

San Antonio Breast Cancer Symposium

Accelerated partial breast irradiation following lumpectomy was marginally not found to be equivalent to whole breast irradiation to control ipsilateral breast tumor recurrence.

December 7th 2018, 12:35am

San Antonio Breast Cancer Symposium

A longer duration of chemotherapy exposure was possible in patients with metastatic triple-negative breast cancer who received trilaciclib, an investigational CDK4/6 inhibitor, in addition to gemcitabine and carboplatin (GC) compared with GC alone.

December 7th 2018, 12:17am

San Antonio Breast Cancer Symposium

The use of low-dose tamoxifen was shown to significantly reduce the risk of new and recurrent disease following surgery in women diagnosed with breast intraepithelial neoplasia but it did not cause more serious adverse events compared with placebo.